Galway is the medtech capital of Europe. That is not a marketing claim — it is a description of a physical reality built over forty years of sustained investment by the world's largest medical device companies, reinforced in 2026 by two significant announcements that signal continued confidence in the city's position.
The Two Announcements That Matter
In May 2026, Medtronic — whose principal executive office is in Galway and which has invested approximately €11 billion in Ireland over the past forty years, including €1.2 billion in research and development — announced the establishment of a European software hub in Galway focused on care systems for cardiac patients.
The move follows Medtronic's expansion of its London office into a global hub for artificial intelligence and robotics in surgery. The Galway software hub is a complementary investment — positioning Ireland specifically within Medtronic's digital health and connected care strategy.
In April 2026, Boston Scientific announced plans to invest $88.5 million to expand its research and development capabilities in Galway. Boston Scientific has been one of the most consistent investors in the Irish medtech ecosystem, and this latest commitment reinforces the company's view of Galway as a strategic location for device innovation.
Together, these two announcements represent a clear signal from two of the world's largest medtech companies: Ireland's position is not being reconsidered. It is being deepened.
The Indigenous Sector Is Growing
Alongside the multinational investment, Ireland's indigenous medtech sector is producing companies of genuine global ambition.
ICS Medical Devices, a Galway-based catheter manufacturer founded in 2019, announced the creation of 72 new jobs by 2028, supported by €1.5 million in Enterprise Ireland funding. The company specialises in contract design, development and manufacturing for minimally invasive catheter technologies serving the structural heart, neurovascular and endovascular therapy markets.
AuriGen Medical, also based in Galway, is developing a first-of-its-kind implant that integrates stroke prevention, arrhythmia management and heart failure monitoring into a single device with smart sensors transmitting real-time data to clinicians.
LaNua, a UCD spin-out founded in 2024, raised $6.3 million in seed funding to develop a next-generation device for treating internal bleeding, vascular malformations and tumours.
These companies represent a new generation of Irish medtech — university spin-outs and indigenous startups addressing specific clinical problems with genuinely novel technology, backed by Enterprise Ireland and international venture capital.
The Tariff Exposure
US tariffs on medical devices are applying €1.2 billion in additional costs to Irish medtech products exported to the American market, according to Ibec's Irish Medtech pre-budget submission. This is a real and material pressure on companies whose primary market is the United States.
The industry's response has been to press for expanded R&D tax credits, investment in talent development and the establishment of a dedicated Office of Life Sciences within the Department of Enterprise, Tourism and Employment — three budget priorities identified as critical to maintaining competitiveness under increased trade pressure.
Research Ireland's €17 Million Infrastructure Investment
In April 2026, Research Ireland announced €17 million in infrastructure investment across AI, medtech and related fields. The allocation includes €1.97 million for a national medical device innovation research facility, developed in partnership between the University of Galway and RCSI — two institutions already at the heart of Ireland's medtech ecosystem.
The investment signals continued state commitment to building the research infrastructure that connects academic innovation with commercial application — the pipeline through which the next generation of Irish medtech companies will emerge.
The Bottom Line
Ireland's medtech sector in 2026 is defined by a combination of multinational depth and indigenous ambition that few European countries can match. The Medtronic and Boston Scientific announcements are the headline acts. The ICS Medical, AuriGen and LaNua stories are the ones that will define the sector's next chapter.
Galway's position as Europe's medtech capital is not merely historical. It is being actively renewed — by the companies investing here, the researchers building here and the state supporting the infrastructure that makes it possible.
Health Pulse covers Ireland's health system, pharma and life sciences industry. Subscribe to the Health Pulse Briefing — every Wednesday.
← Back to Health Pulse